obesity drug news today glp-1 september 2025 Weight-Loss Demonstration Begins July 2026 New oral GLP-1 drugs could
Description
The prevalence of obesity in the USA has been increasing over the past few decades, and despite the availability of approved anti-obesity medications (AOMs), people with obesity may not be accessing or receiving treatment at levels consistent with the disease prevalence
Each has a different safety profile
How they work: Your pancreas has beta cells that produce insulin
Tachyphylaxis - where the body responds less to repeated doses - often helps symptoms get better over time
Young adult male patients with childhood-onset IBD have increased risks of compromised cortical and trabecular bone microstructures
